Navigation Links
Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Date:6/12/2009

WOODCLIFF LAKE, N.J., June 12 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that Thomas P. Rice has been elected to the company's board of directors. Mr. Rice was also appointed to the Audit Committee and the Nominating-Corporate Governance Committee.

Currently, Mr. Rice is a principal and co-founder of Columbia Investments LLC, Baltimore, Maryland, which invests in local businesses in Maryland. From February 2004 to November 2006, he was the Chief Executive Officer of Andrx Corporation when Andrx was sold to Watson Pharmaceuticals. He was also a director of Andrx from April 2003 until November 2006. Mr. Rice is currently a director of Chemed Corporation, the owner of two wholly-owned subsidiaries: VITAS Healthcare Corporation and Roto-Rooter. Mr. Rice has an M.S. in Finance from Loyola College and a B.S. from the University of Maryland. He is also a Certified Public Accountant.

Patrick G. LePore, Par's Chairman, President and Chief Executive Officer, said, "We are very pleased to welcome Tom to our board of directors. Tom is a proven and successful executive whose extensive knowledge of generic and branded pharmaceutical operations will bring valuable insight to our board."

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Thomas R. Frieden, M.D., M.P.H., Begins Role as CDC Director and ATSDR Administrator
2. Go Healthy Receives Letter of Endorsement from the Texas Chiropractic Association, District Five State Director - Dr. Thomas Klesmit
3. ASPH Supports President Obamas Selection of New York City Health Commissioner Thomas R. Frieden, MD, MPH, for CDC Director
4. Statement from CCF Against CDC Nominee Thomas Frieden
5. Trust for Americas Health Supports Appointment of Thomas Frieden to Lead CDC
6. Michael DeMane Joins Thomas, McNerney & Partners as Senior Advisor
7. Nashville's eDoc4u Signs Partnership Agreement With Saint Thomas Health Services
8. Availity Promotes Russ Thomas to President and Chief Operating Officer
9. Guy's and St Thomas' NHS Foundation Trust extends patient care benefits of BigHand Digital Dictation
10. Thomas C. Barber, MD, Elected Chair of Academy Board of Councilors
11. SCANs Thomas Lescault Elected President of New Arizona Association of Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive ... now meet with Dr. Joseph Bedich for a consultation, with or without a referral. ... oral health and functionality. , Dr. Bedich offers a variety of cosmetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... Brentwood, TN (PRWEB) , ... May 24, 2017 ... ... announced the addition of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first ... and security of every IT system, from the datacenter to the cloud to ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: